

IJK PORTFOLIO UPDATE

Quarterly Portfolio Review September xx, 20xx

Table of Contents

Part I	
Section I: IJK Performance Dashboards	
Part II	
Section I: ABC Fund (Project XYZ)	
Section II: DEF Fund (Project)*	20
Section III: GHI Fund (Project) *	24
Section IV: JKL Fund (Project) *	28
Section V: MNO Fund (Project) *	32
Part III	
Appendix I: ABC FUND Company Summaries	37
Comp1	38
Comp2	39
Comp3 *	40
Comp4 *	41
Comp5 *	42
Comp6 *	43
Appendix II: DEF FUND Company Summaries	
Comp7 *	45
Comp8 *,,,.	46
Appendix III: GHI FUND Company Summaries	47
Comp9 *	48
Comp10 *	49
Comp11 *	50
Comp12 *	51
Appendix IV: JKL FUND Company Summaries	52
Comp13 *	53
Comp14 *	54
Comp15 *	55
Appendix V: MNO FUND Company Summaries	56
Comp16 *	
Comp17 *	
Comp18 *	
Appendix VI: Structure Charts *	


* excluded from sample

Part I

Section I: IJK Performance Dashboards





IJK QoQ Change in Total Value by Deal (Net - Gross)



IJK Performance Dashboard

IJK QoQ Change in Total Value by Vehicle (Net - Gross)





1. Total exposure is IJK A + IJK B + IJK C + Vehicle1 co-investment stake + Vehicle 2 co-investment stake. *Values in USD million. Values in USD million.



Values in USD million.


IJK Exposure by Asset Dashboard (Unrealized – September xx, 20xx)



Values in USD million.

Fund Logo





Fund Logo

1. Total exposure is IJK A + IJK B + IJK C. Values in USD millions



IJK A Projected Performance by Deal

IJK A Projected Performance by Vehicle

IJK	(A	IJł	КВ	IJ	K C	Vehicle	1 Co-Inv
Current Valuation	Projected Returns	Current Valuation	Projected Returns	Current Valuation	Projected Returns	Current Valuation	Projected Returns
Net - Gross Net - Gross MolC IRR							
Projected Exit Pr	oceeds by Deal	Projected Exit P	roceeds by Deal	Projected Exit P	roceeds by Deal	Vehicle	2 Co-Inv
LMO		LMO	ABC	DEF		Current Valuation	Projected Returns
PQR XYZ	ABC		XYZ XM PQR	5)	ABC	Net - Gross Net - Gross MolC IRR	Net - Gross Net - Gross MolC IRR

IJK Performance Dashboard

ABC Q3 20xx Valuations

All figures in USD millions, unless otherwise stated

	R	eference	Date NAV	(Dec-20xx)				IJK Entry	(Nov-20xx)						As Of	Sep-xx				
					EV /		% of Dec						EV /								
		Implied		20xxA	20xxA	Entry	20x x	Follow-	Total	Implied	Net	20xxA	20xxA	Total	Implied		LTM	EV / LTM	Gross	∆ in EBITD	A since
Company Name	NAV	EV	Net Debt	EBITDA	EBITDA	Price	NAV	On	Cost	EV	Debt ⁽¹⁾	EBITDA	EBITDA	Value ⁽²⁾	EV	Net Debt	EBITDA	EBITDA	MoIC	Reference	e Date
Comp1 (3)	XX	X	K XX	XX	X.Xx	XX	Х%	, -	XX	XX	XX	(XX	X.Xx	XX	X X	(X)	(Х	X X.Xx	X.XXx	na	na
Comp2																					
Comp3 (4)																					
Comp6																					
Comp7																					
Comp5																					
Comp4 ⁽⁵⁾																					
Comp8																					
Subtotal	1																				
Comp24 ⁽⁶⁾	1				-																
Total	1				-																
	1				P														4		

XYZ Q3 20xx Valuations

All figures in USD millions, unless otherwise stated

		Reference	Date NAV	(Jun-20x)	()				IJK Entry	(Aug-20xx)						As Of S	Sep-xx				
							% of Dec.					20xxA									
		Implied		LTM	EV / LTM	Entry	20x x	Follow-	Total	Implied	Net	LTM	EV / LTM	Total	Implied		LTM	EV / LTM	Gross	∆ in EBITDA	A since
Company Name	NAV	EV	Net Debt	EBITDA	EBITDA	Price	NAV	On	Cost	EV	Debt ⁽⁷⁾	EBITDA	EBITDA	Value ⁽²⁾	EV	Net Debt	EBITDA	EBITDA	MoIC ⁽⁸⁾	Reference	Date
Comp9	XX	X	(XX	(X)	<u> X Xx</u>	XX	Х%	-	XX	XX	XX	X X	X X.Xx	XX	(X)	K XX	X X	(XXx	X XXx	na	na
Comp10																					
Comp11																					
Comp12																					
Comp13 ⁽⁹⁾																					
Other Assets (10)																					
Total																					

PQR Q3 20xx Valuations

All figures in USD millions, unless otherwise stated

	R	eference	Date NAV	(Mar-20x)	K)				IJK Entry (Apr-20xx)						As Of S	Sep-xx				
Company Name	NAV	Implied EV	Net Debt	LTM EBITDA	EV / LTM EBITDA	Entry	% of Mar. 20x x NAV	Follow- On	Total Cost	EV	Net Debt ⁽⁶⁾	20xxA EBITDA	EV / LTM EBITDA		Implied EV	I Net Debt	LTM EBITDA	EV / LTM EBITDA		∆ in EBITD Reference	
Comp16	XX	X	(XX	< X	K X.Xx	XX	Х%	-	XX	X	(X)	K X	X X.Xx	X	(X	x xx	X	K X.Xx	X.XXx	na	na
Comp17																					
Comp16																					
Comp19																					
Comp18																					
Comp20																					
Comp21 (11)																					
Comp22																					
Total																					

Notes:

- (1) ABC net debt figures at entry are as of December xx, 20xx
- (2) Total Value represents Q2 20xx NAV plus previous realizations
- (3) Comp1 net debt as of the Reference Date marked "na" since it does not include the CompA merger
- (4) Comp3 20xxA and 20xxA EBITDA represent calendar year
- (5) Current valuation for Comp4 at projected EBITDA
- (6) Investment made on June xx, 20xx. Investment was made only through CompB SPV
- (7) XYZ and PQR net debt figures at entry are as of December xx, 20xx
- (8) XYZ Gross MolC reflects 100% ownership of both Fund BCD and Fund XYZ. JJK's exposure to XYZ has a higher percentage ownership of BCD which results in an IJK XYZ MolC of X.XXx
- (9) Comp13 Reference Date LTM EBITDA is pro forma for the sale of the terminal asset and Reference Date NAV is reduced for proceeds received after the Reference Date for the terminal sale
- (10) Includes residual position in GHI ITN EBITDA metrics are based on a 2 year average due to the volatility of political cycles on annual performance
- (11) Target2 and Target3 metrics "na" at entry since these assets were acquired post close as part of the contingent portfolio acquisition which closed in July 20xx

BCD Q3 20xx Valuations

All figures in USD millions, unless otherwise stated

	F	Reference	Date NAV	(Dec-20xx	:)				IJK Entry	(Apr-20xx)						As Of S	Sep-xx				
						G	% of Dec.					Q1 20xx									
		Implied		LTM	EV / LTM	Entry	20x x	Follow-	Total	Implied		LTM	EV / LTM	Total	Implied		LTM	EV / LTM	Gross	∆ in EBITDA	A since
Company Name	NAV	EV	Net Debt	EBITDA	EBITDA	Price	NAV	On	Cost	EV	Net Debt	EBITDA	EBITDA	Value	EV	Net Debt	EBITDA	EBITDA	MolC	Reference	Date
Comp25	XX	XX	XX XX	XX	X.Xx	XX	Х%	-	XX	XX	XX XX	XX	X.Xx	XX	x x	(XX	X	(X.Xx	X.XXx	na	na
Comp26																					
Comp27																					
Comp28 ⁽³⁾																					
Comp29																					
Total																				<u></u>	

LMO Q3 20xx Valuations

All figures in USD millions, unless otherwise stated

	F	Reference	Date NAV	(Dec-20xx)				IJK Entry	(Aug-20xx)						As Of S	Бер-хх				
						9	% of Dec.					Q1 20xx									
		Implied		LTM	EV / LTM	Entry	20xx	Follow-	Total	Implied	Net	LTM	EV / LTM	Total	Implied		LTM	EV / LTM	Gross	∆ in EBITDA	since
Company Name	NAV	EV	Net Debt	EBITDA	EBITDA	Price	NAV	On	Cost	EV	Debt	EBITDA	EBITDA	Value	EV	Net Debt	EBITDA	EBITDA	MolC	Reference	Date
Comp30	XX	XX	XX XX	XX	X.Xx	XX	Х%	-	XX	XX	XX	X	(X.Xx	XX	(XX	(XX	X	(XXx	X.XXx	na	na
Comp31																					
Comp34																					
Comp32																					
Comp33																					
Total	L																				

UVW Q3 20xx Valuations

All figures in USD millions, unless otherwise stated

	R	Reference	Date NAV	(Dec-20xx)				IJK Entry (Sept-20xx)						As Of S	бер-хх				
					EV /	q	% of Dec.														
		Implied		20xxA	20xxA	Entry	20x x	Follow-	Total	Implied	Net	20xxA	EV / LTM	Total	Implied		LTM	EV / LTM	Gross	∆ in EBITDA	A since
Company Name	NAV	EV	Net Debt	EBITDA	EBITDA	Price	NAV	On	Cost	EV	Debt	EBITDA	EBITDA	Value ⁽²⁾	EV	Net Debt	EBITDA	EBITDA	MolC	Reference	Date
Comp35	XX	XX	XX XX	XX	X.Xx	XX	Х%	-	XX	XX	XX	X	(XXx	XX	XX	XX	XX	X.Xx	X.XXx	na	na
Comp36																					
Comp37																					
Comp38																					
Comp39																					
Total	L					L															

Blended price based on deferred vs. cash offer take up
 Reference Date NAV is JIK FMV estimate
 Reference Date Net Debt as of April 20xx closing
 Note: FX rate for UVW as of September xx, 20xx of 1 EUR = X.X USD

Part II

Section II: ABC Fund (Project XYZ)

ABC Fund (Project XYZ)

Overview

IJK Investee Fund Name:	Investment Period:	
GP Name:	Predecessor Fund Vintage:	
Fund Domicile:	IJK Role:	
Fund Term:	IJK Total Commitments:	
# of Portfolio Companies:	Total Fund Size:	
Transaction Date:	IJK % of ABC Fund:	

Performance Summary

			IJK Commit	ments			IJK Value		
(in \$m)	Total Commitments	Original Unfunded Commitments	Canceled Unfunded Commitments ⁽⁴⁾	Current Unfunded Commitments	Investment Cost ⁽⁵⁾	Realized Proceeds ⁽⁶⁾	Unrealized Value	Total Value	% of Total
Investment Vehicle									
IJK ⁽¹⁾	XXX	XXX	XXX	ЖX	ЖX	ЖX	ЖX	XXX	Х%
IJK A ⁽²⁾									
IJK B ⁽³⁾									
Total						-			
	% of ABC Fund			% Unfunded	% Invested	DPI ⁽⁷⁾	RVPI ⁽⁸⁾	TVPI ⁽⁹⁾	IRR ⁽¹⁰⁾
Gross - Gross Returns									
Net - Gross Returns									

(1) IJK's Subsidiary1: Based on IJK B's initial close amount of \$XX.Xm (3) IJK Strategic Secondaries Subsidiary2

(4) ABC canceled 26% of the unfunded commitments since the Fund has no remaining unfunded commitment to Comp3 (5) Investment Cost excludes Fund Expenses (6) Proceeds primarily from Comp1 Options' June 20xx dividend recapitalization (7) DPI stands for distributions to paid-in capital (8) RVPI stands for residual value to paid-in capital (9) TVPI stands for total value to paid-in capital (10) IRR is net of ABC management fees and carry

Key Updates


- Comp1 (X% of NAV) YTD Sept 20xx revenue and EBITDA were X% and (X%) above and below prior year comparable period, respectively. The revenue outperformance was a result of continued core contract growth but margins continue to underperform due to mispriced contracts. Unexpected increased LMN Ratios and rising operating expenses compared to budget have been driven by the accelerated influx of patients combined with increased treatment entitlements (minimum treatment days). The reduction of contract profitability particularly in the Region1, as well as increased labor and benefit costs has decreased earnings expectations for 20xxF
- Comp3's (X% of NAV) public share price traded up in the quarter to \$XX.XX, Comp3's share price is X% above IJK's entry price. As discussed previously, in July 20xx Comp3 announced the acquisition of Target1 which complemented the existing business by bringing substantial access and presence to the Food and Beverage market. As part of the transaction the Target1 CEO became the merged corporation's CEO in October 20xx
- Comp7 (X% of NAV) YTD Sept 20xx revenue and EBITDA were [X]% and [X]% above with prior year comparable period, respectively. Growth is attributable to impact of HIJ contract win in December 20xx, the contract was rapidly on boarded in 20xx as well as increased growth of their reprocessing division and TUV division
- Comp8 (6% of NAV) YTD Sept 20xx revenue and EBITDA were X% and X% higher than the comparable period in 20xx, as the business continues to rebound from the resurgence in AAA activity by BBB companies and benefit from cost savings reduction initiatives undertaken throughout the downturn

Internal Commentary

- Comp1: Please see Q3 20xx Comp1 Supplement for full details. Management has instituted a new 5 year plan for the business, pushing the expected sale process to begin at the end of 20xx (selling off of 20xx forecast). 20xxB was predicated on significant regional pricing improvements not certain at the time and which did not materialize.
- Comp3: Please see Q3 20xx Comp3 Supplement for full details. Target1 acquisition is expected to bring run-rate accretion to EPS of \$XX.X of ~X% uplift to current Comp3 standalone EPS
- Comp4: DCP projects 20xxE results to be \$XX.X million, and YTD Comp4 is tracking above budget. Additionally, SE implant distribution business is rolling out across Comp5 in Q1 20xx, and has received interest from 2 other hospital systems
- Comp7: Management increased their 20xxF upwards to \$XX.X million, as previously the initial 20xx budget was \$XX million. The Company is on track to hit their new forecast, as the business continues to outperform

ABC Fund (Project XYZ)

Value Breakdown




Summary of Investments as of September xx, 20xx

(in \$m)	Location	Industry	Invested Capital	% of Invested Cost	Realized Proceeds (US\$)	DPI ⁽¹⁾	Unrealized Proceeds	% of Unrealized Proceeds	Total Value	TVPI ⁽²⁾
Comp1	Location1	Industry1	XX.X	X%	XX.X	X.XXx	XX.X	X%	XX.X	X.XXx
Comp2	Location2	Industry2	XX.X	X%	XX.X	X.XXx	XX.X	X%	XX.X	X.XXx
Comp3	Location3	Industry3	XX.X	X%	XX.X	X.XXx	XX.X	X%	XX.X	X.XXx
Comp4	Location4	Industry4	XX.X	X%	XX.X	X.XXx	XX.X	X%	XX.X	X.XXx
Comp5	Location5	Industry5	XX.X	×%	XX.X	X.XXx	XX.X	X%	XX.X	X.XXx
Comp6	Location6	Industry6	XX.X	×%	XX.X	X.XXx	XX.X	X%	XX.X	X.XXx
Comp7	Location7	Industry7	XX.X	×%	XX.X	X.XXx	XX.X	X%	XX.X	X.XXx
Comp8	Location8	Industry8	XX.X	X%	XX.X	X.XXx	XX.X	X%	XX.X	X.XXx
Total Gross			XX.X	X%	XX.X	X.XXx	XX.X	X%	XX.X	X.XXx
Total Net-Gross			XX.X	X%	XX.X	X.XXx	XX.X	X%	XX.X	X.XXx

(1) DPI stands for distributions to paid-in capital


(2) TVPI stands for total value to paid-in capital

Portfolio Companies Total Value Bridge (Whole Fund Basis)



(1) Includes cost realization for assets

Value Creation Bridge since Reference Date (Whole Fund Basis)



(1) Includes follow – on investment in Comp5

(2) Other Adjustments include NOLs, option proceeds, management fees and exit fees

(3) Includes cost realization for Assets

ABC Reforecast Analysis

ABC Reforecast Analysis

	Section 1: Portfolio company projections (unrealised)	Section 2: Notes
Beacon Health Options Revenues EBITDA Net Debt	2011 2012 <th< th=""><th> Comp1 sold in 20xx with new management X year projections and updated exit valuation to reflect current transaction/trading in space Comp2 sold at \$X.XX per share at end of 20xx, projections shown do not reflect only ABC business </th></th<>	 Comp1 sold in 20xx with new management X year projections and updated exit valuation to reflect current transaction/trading in space Comp2 sold at \$X.XX per share at end of 20xx, projections shown do not reflect only ABC business
Comp3 Revenues EBITDA Net Debt	2011 2011 <th< td=""><td> without Target1 BCD updated for new run-rate EBITDA at ~X,X EV/EBITDA Comp3 sold at Management revised 20xx expectations for business at X,Xx </td></th<>	 without Target1 BCD updated for new run-rate EBITDA at ~X,X EV/EBITDA Comp3 sold at Management revised 20xx expectations for business at X,Xx
Suture Express Revenues EBITDA Net Debt	2011 2012 2011 <th< td=""><td>GHI exit at current NAV after XX elections</td></th<>	GHI exit at current NAV after XX elections
	Section 2. Detailed return projections	

Section 3: Detailed return projections

		Capital	deployed						Ret	urns					Actual / Ex	pected cash I	lows (Dec)					
				Final exit	Hold				EV /	Total	Profit /											
US\$m - unless stated	Status	Entry cost	Total cost	date	period	E۷	Net debt	EBITDA	EBITDA	proceeds	(loss)	CoC	IRR	Entry	20xx	20xx	20xx	20xx	20xx	20xx	20xx	20xx
Comp1	Active	X.X	X.X	Mar-XXE	X.X yrs	X.X	X.X	X.X	X.Xx	X.X	X.X	X.X	X.X2	X.X	X.X	X.X	X.X	X.X	X.X	X.X	X.X	X.X
Comp2	Realized Q2		,									-										
Comp3	Active																					
Comp4	Realized Q3																					
Comp5	Active																					
Comp6	Active																					
Comp7	Active																					
Comp8	Active																					
DCP Pooling Gross																						
Transaction Costs																						
Diamond Castle Mgmt Fees Drawn																						
Diamond Castle Carry																						
DCP Pooling Net-Gross																						

Section 4: Summary historical and projected valuations (Net-Gross)

Valuation Date	Q4 20XX	Q1 20XX	Q2 20XX	Q3 20XX	Q4 20XX	Q1 20XX	Q2 20XX	Q3 20XX	Q4 20XX	Q1 20XX	Q2 20XX	Q3 20XX
Reforecast Date	 Nov-XX	Nov-XX	Not-XX	Nov-XX	Nov-XX	Nor-XX	Sep-XX	Sep-XX	Feb-XX	Jun-XX	Sep-XX	Dec-XX
Concert estestion												
DPI	X.Xx	X.Xx	X.Xx	X.Xx	X.Xx	X.Xx	X.Xx	X.Xx	X.Xx	X.Xx	X.Xx	X.Xx
RVPI												
TVPI												
Forecast												
CoC												
IRB												
Implied duration												

Part III

Section I: ABC Fund Company Summaries

Comp1

Business Description

Comp1 is a publicly-traded, provider of premium labels for the home and personal care, food and beverage, and specialty consumer products markets. The company serves international brand owners in Country1, Country2, etc.

Historical Comp1 Share Price Chart



Overview

EV	RFC	Gross MolC	
EV / EBITDA	Expe	ected Exit Multiple	
Fund Equity Ownership ⁽¹⁾ :	RFE	Expected Exit Date	

(1) Includes dilution from management options and equity incentive units at the current valuation, where appropriate

IJK Total Exposure

(in \$m)	Investment Cost	Realized Proceeds	DPI ⁽¹⁾	Unrealized Value	RVPI ⁽²⁾	Total value	TVPI (3)
Comp2	XX.X	XX.X	X.XXx	XX.X	X.XXx	XX.X	X.XXx

(1) DPI stands for distributions to paid-in capital (2) RVPI stands for residual value to paid-in capital (3) TVPI stands for total value to paid-in capital

Financials

		YTD on YTD			LTM on LTM		Year on Year							
	YTD to	YTD to	Δ 'xxA to	LTM to	LTM to	Δ'xxAto	20xxA	20	20xxA	Mgmt	IJK	Δ 'xxA to		
	September	September	'xxxA	September	September	'xxxA	20004	20xxA	20004	Forecast ⁽¹⁾	Forecast ⁽²⁾	IJK 'xxF		
EBITDA	XX.X	XX.X	Х%	XX.X	XX.X	Х%	XX.X	XX.X	XX.X	XX.X	XX.X	Х%		
Margin %														
Net debt / (Cash)														
Net debt / EBITDA														

Note: Financials shown as reported and include the results of acquisitions closed

(1) FY20xx forecast is based on consensus forecast amongst analysts covering Comp1. Source: Capital IQ as of December xx, 20xx

(2) IJK Reforecast assumes exit at NAV

Key Updates

- The share price increased from \$XX.XX a share at Q1 20xx fiscal period end (June xx, 20xx) to \$XX.XX at Q2 20x period end. At \$XX.XX a share, Comp1's share price is X% above IJK's entry price of \$XX.XX
- As discussed previously, in July 20xx Comp1 announced the acquisition of Target1 Labels which complemented the
 existing business by bringing substantial access and presence to the Food and Beverage market. As part of the
 transaction the Target1 CEO became the merged corporation's CEO in October 20xx

Internal Commentary

- Please see Q3 20XX Comp1 Supplement for full details
- Target1 acquisition is expected to bring run-rate accretion to EPS of \$XX.XX of ~X% uplift to current Comp1 standalone EPS
- ABC previously was evaluating senior management change and Target1 CEO was the optimal candidate for the position

Business Description

Comp2 is a specialty distributor of suture, endo-mechanical and other disposable wound closure products to hospitals and surgery centers across the US. Comp2's lean operations and single-site model enable it to provide overnight delivery through its longstanding partnership with Partner1 and to achieve 99+% fill rates, resulting in a high level of customer satisfaction and loyalty.

Overview

EV	RF Gross MolC	
EV / EBITDA	Expected Exit Multiple	
Fund Equity Ownership ⁽¹⁾ :	RF Expected Exit Date	

(1) Includes dilution from management options and equity incentive units at the current valuation, where appropriate

IJK Total Exposure

(in \$m)	Investment Cost	Realized Proceeds	DPI ⁽¹⁾	Unrealized Value	RVPI ⁽²⁾	Total value	TVPI(3)
Comp2	XX.X	XX.X	X.XXx	XX.X	X.XXx	XX.X	X.XXx

(1) DPI stands for distributions to paid-in capital (2) RVPI stands for residual value to paid-in capital (3) TVPI stands for total value to paid-in capital

Financials

	YTD on YTD				LTM on LTM		Year on Year							
	YTD to	YTD to	Δ 'xxA to	LTM to	LTM to	Δ 'xxA to	20xxA	20xxA	20xxA	Mgmt	IJK	∆ 'xxA to		
	September	September	'xxA	September	September	'xxA		20004	20004	Forecast ⁽¹⁾	Forecast ⁽²⁾	IJK 'xxF		
EBITDA	XX.X	XX.X	Х%	XX.X	XX.X	Х%	XX.X	XX.X	XX.X	XX.X	XX.X	Х%		
Margin %														
Net debt / (Cash)														
Net debt / EBITDA														

(1) 20xxF is the full year budget as of March 20xx. 20xxF Net debt / (Cash) is based on FY 20xx actual net debt

(2) IJK 20xx reforecast is as of December 20xx

Key Updates

- Comp1 (X% of NAV) YTD Sept 20xx revenue and EBITDA were X% and (X%) above and below prior year comparable period, respectively. The revenue outperformance was a result of continued core contract growth but margins continue to underperform due to mispriced contracts. Unexpected increased LMN Ratios and rising operating expenses compared to budget have been driven by the accelerated influx of patients combined with increased treatment entitlements (minimum treatment days). The reduction of contract profitability particularly in the Region1, as well as increased labor and benefit costs has decreased earnings expectations for 20xxF
- Comp3's (X% of NAV) public share price traded up in the quarter to \$XX.XX, Comp3's share price is X% above IJK's entry price. As discussed previously, in July 20xx Comp3 announced the acquisition of Target1 which complemented the existing business by brining substantial access and presence to the Food and Beverage market. As part of the transaction the Target1 CEO became the merged corporation's CEO in October 20xx

Internal Commentary

- Comp1: Please see Q3 20xx Comp1 Supplement for full details. Management has instituted a new 5 year plan for the business, pushing the expected sale process to begin at the end of 20xx (selling off of 20xx forecast). 20xxB was predicated on significant regional pricing improvements not certain at the time and which did not materialize.
- Comp3: Please see Q3 20xx Comp3 Supplement for full details. Target1 acquisition is expected to bring run-rate accretion to EPS of \$XX.X of ~X% uplift to current Comp3 standalone EPS